IL175615A0 - Pharmaceutical compositions and kits containing a cholinesterase inhibitor and an antidepressant - Google Patents

Pharmaceutical compositions and kits containing a cholinesterase inhibitor and an antidepressant

Info

Publication number
IL175615A0
IL175615A0 IL175615A IL17561506A IL175615A0 IL 175615 A0 IL175615 A0 IL 175615A0 IL 175615 A IL175615 A IL 175615A IL 17561506 A IL17561506 A IL 17561506A IL 175615 A0 IL175615 A0 IL 175615A0
Authority
IL
Israel
Prior art keywords
antidepressant
pharmaceutical compositions
kits containing
cholinesterase inhibitor
cholinesterase
Prior art date
Application number
IL175615A
Other languages
English (en)
Original Assignee
Theracos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theracos Inc filed Critical Theracos Inc
Publication of IL175615A0 publication Critical patent/IL175615A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL175615A 2003-11-19 2006-05-14 Pharmaceutical compositions and kits containing a cholinesterase inhibitor and an antidepressant IL175615A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52361003P 2003-11-19 2003-11-19
US10/993,496 US20050143350A1 (en) 2003-11-19 2004-11-18 Combination drug therapy to treat obesity
PCT/US2004/038981 WO2005051297A2 (en) 2003-11-19 2004-11-19 Combination drug therapy to treat obesity

Publications (1)

Publication Number Publication Date
IL175615A0 true IL175615A0 (en) 2008-04-13

Family

ID=34636478

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175615A IL175615A0 (en) 2003-11-19 2006-05-14 Pharmaceutical compositions and kits containing a cholinesterase inhibitor and an antidepressant

Country Status (11)

Country Link
US (1) US20050143350A1 (https=)
EP (1) EP1684712A4 (https=)
JP (1) JP2007511611A (https=)
KR (1) KR20060109493A (https=)
AU (1) AU2004293008A1 (https=)
BR (1) BRPI0416700A (https=)
CA (1) CA2545655A1 (https=)
IL (1) IL175615A0 (https=)
RU (2) RU2363458C2 (https=)
SG (1) SG148169A1 (https=)
WO (1) WO2005051297A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US20070166363A1 (en) * 2004-02-19 2007-07-19 Lane Roger M Use of cholinesterase inhibitors for treating vascular depression
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US7968538B2 (en) * 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2007012154A1 (en) * 2005-07-27 2007-02-01 Carlos Henrique Horta Lima Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties.
ES2362926T3 (es) * 2005-09-22 2011-07-15 EISAI R&D MANAGEMENT CO., LTD. Nueva combinación de fármacos como un antidepresivo.
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
RU2452474C2 (ru) * 2006-12-01 2012-06-10 Нитто Денко Корпорейшн Стабилизированная адгезивная композиция, содержащая донепезил
US20100062045A1 (en) * 2006-12-01 2010-03-11 Nitto Denko Corporation Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed
AU2008302190A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
CA2723949A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal
RU2481826C2 (ru) * 2008-05-30 2013-05-20 Нитто Денко Корпорейшн Содержащий донепезил адгезивный препарат и упаковка для него
CN102046171B (zh) * 2008-05-30 2013-06-19 日东电工株式会社 经皮吸收制剂
US8633252B2 (en) * 2009-01-26 2014-01-21 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
SMT201700578T1 (it) 2009-11-20 2018-01-11 Tonix Pharma Holdings Ltd Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina
US8440655B2 (en) 2010-06-21 2013-05-14 Theracos, Inc. Combination therapy for the treatment of diabetes
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
WO2012048243A2 (en) * 2010-10-08 2012-04-12 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
WO2012050348A2 (ko) * 2010-10-13 2012-04-19 한국과학기술원 역률보상형 엘이디 조명장치
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
US20150157672A1 (en) * 2013-12-09 2015-06-11 Phytology Labs, Inc. Kits and methods for sustained weight loss
WO2015120299A1 (en) 2014-02-07 2015-08-13 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
US20190175610A1 (en) * 2017-12-07 2019-06-13 Glykon Technologies Group, Llc Formulation of galantamine and carnitine and method of fatty acid mobilization
MX2020006140A (es) 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
KR20250099037A (ko) * 2023-12-21 2025-07-01 주식회사 에아스텍 리코라민을 유효성분으로 함유하는 혈전 관련 질환 또는 대사성 질환의 예방, 개선 또는 치료용 조성물
WO2025245102A2 (en) * 2024-05-21 2025-11-27 S1 Biopharma, Inc. Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3673177A (en) * 1970-05-04 1972-06-27 American Cyanamid Co Substituted 4-(anilinomethylene)-3-galanthamaninones
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4895845A (en) * 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
EP0567090B1 (en) * 1992-04-24 2000-07-26 Takeda Chemical Industries, Ltd. Benzoxazepine derivatives as cholinesterase inhibitors
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
TW248556B (https=) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE69429895T2 (de) * 1993-06-28 2002-08-29 American Home Products Corp., Madison Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
RU2161159C2 (ru) * 1994-11-02 2000-12-27 Жансен Фармасетика Н.В. Замещенные тетрациклические производные оксазепина и тиазепина, способ их получения, композиция, обладающая антипсихотической активностью, и способ ее получения
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
IL131713A (en) * 1997-03-11 2004-08-31 Arakis Ltd Dosage forms comprising separate portions of r- and s-enantiomers
CA2282390A1 (en) * 1997-04-17 1998-10-22 Yukio Fujisawa Thermogenic composition and benzazepine thermogenics
US5795895A (en) * 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
US6313919B1 (en) * 1997-07-02 2001-11-06 Canon Kabushiki Kaisha Printing control apparatus and method
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6688640B1 (en) * 1999-08-17 2004-02-10 Lear Corporation Tethered air bag cover
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US20010043957A1 (en) * 2000-02-25 2001-11-22 Morris Mann Lypolytic composition
EP1132389A1 (en) * 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
DOP2001000154A (es) * 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
US6533540B1 (en) * 2000-06-09 2003-03-18 Sta-Rite Industries, Inc. Double-seal/oil-reservoir system for a motor/pump assembly
CA2354877C (en) * 2000-08-18 2006-05-02 H. Lundbeck A/S Method for the preparation of citalopram
ES2194597B2 (es) * 2002-01-25 2004-08-01 Esteve Quimica, S.A. Procedimiento para la obtencion de citalopram.

Also Published As

Publication number Publication date
WO2005051297A2 (en) 2005-06-09
BRPI0416700A (pt) 2007-03-06
KR20060109493A (ko) 2006-10-20
JP2007511611A (ja) 2007-05-10
RU2006121453A (ru) 2008-01-10
WO2005051297A3 (en) 2006-07-20
AU2004293008A1 (en) 2005-06-09
US20050143350A1 (en) 2005-06-30
EP1684712A4 (en) 2009-04-22
SG148169A1 (en) 2008-12-31
RU2363458C2 (ru) 2009-08-10
RU2009113038A (ru) 2010-10-20
EP1684712A2 (en) 2006-08-02
CA2545655A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
IL175615A0 (en) Pharmaceutical compositions and kits containing a cholinesterase inhibitor and an antidepressant
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
KR100984939B9 (ko) 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
GB2394894B (en) New use for pharmaceutical composition
IL173639A (en) Ppar-activating compound and pharmaceutical composition containing same
HUP0303313D0 (en) Transdermal pharmaceutical compositions
EP1549316A4 (en) HAMMER OF TFGbeta
AU2003291103A8 (en) Pharmaceutical composition
IL164547A0 (en) Pharmaceutical composition
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
AU2003250372A8 (en) Pharmaceutical composition
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AU2003236353A1 (en) Photopolymerizable composition
AU2003290735A1 (en) Inhibitors of monoamine uptake
IL175292A0 (en) Pharmaceutical composition, containing a beta-3- adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
EP1541139A4 (en) DRUG COMPOSITION WITH NF-KAPPA B HEMMER
IL173176A0 (en) Composition for releasing a weak base for an extended period of time
IL179248A0 (en) Pharmaceutical compositions containing an ice/caspase-1 inhibitor
AP2006003858A0 (en) New association of a sinus node if inhibitor and acalcium inhibitor, and pharmaceutical composition s containing it
GB0311195D0 (en) Glyoxalase inhibitors
EP1585530A4 (en) BIOADHESIVE PHARMACEUTICAL COMPOSITIONS
HUP0300929D0 (en) Analgetic and/or muscle relaxant pharmaceutical composition
GB0217703D0 (en) Pharmaceutical composition
HK1090554A (en) Composition for releasing a weak base for an extended period of time
GB0200815D0 (en) Analgesic compositions